Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
Dr. Durgam most recently served in clinical development leadership roles at
Dr. Durgam graduated with his medical degree from the
“We are very pleased to welcome Dr. Durgam to Intra-Cellular as he brings additional expertise to our clinical programs. We believe his contributions will be invaluable as we continue to advance lumateperone and our pipeline,” said Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies.
“I am excited to join
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease and for the treatment of heart failure.
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Source: Intra-Cellular Therapies Inc.